Name: Arovella Therapeutics (ALA) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ALA

Pharmaceuticals, Biotechnology & Life Sciences

Arovella Therapeutics

Short interest: 0.00%; 0.00 pp 30d; as of 16 June 2026
Reported shorts: 1.8K
Shares on issue: 1.209B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Arovella Therapeutics

Arovella Therapeutics Limited is a biotechnology company developing a platform of invariant Natural Killer T (iNKT) cells for treating cancer. The company aims to harness this platform to create innovative and targeted cancer therapies, positioning itself at the forefront of biotechnology advances. Arovella's unique approach targets unmet medical needs, offering potential breakthroughs in cancer treatment.

Company profile →

Arovella Therapeutics (ASX:ALA) has 0.00% of its shares on issue reported as short positions as of 16 June 2026, or about 1,800 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.06 percentage points. Its highest recorded short interest was 1.99% in April 2014. ALA is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ALA today

Zanger BreakoutWatchScore 25rank 915 of 1942
CAN SLIMWatchScore 10rank 1009 of 1541
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 10rank 1136 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ALA fundamentals

In the year to 30 Jun 2026, Arovella Therapeutics (ASX:ALA) recorded revenue of A$800.0K and a net loss after tax of A$6.9M. A year earlier it recorded revenue of A$136.0K and a net loss after tax of A$7.5M. Year-on-year growth: revenue +488.3% (FY). Net margin −864.5%, return on equity −40.4% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →